Niagen Bioscience develops and commercializes products based on its patented Niagen nicotinamide riboside ingredient, a precursor designed to increase NAD+ levels essential for cellular metabolism and energy production. It markets consumer dietary supplements under the Tru Niagen brand through direct e-commerce and retail channels while also supplying the ingredient to manufacturers and developing pharmaceutical-grade versions. The company conducts clinical research on NAD+ science to support applications in healthy aging.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 31.1 | — | 3.6 | — |
| Q3 2025 | 34 | — | 4.6 | — |
| Q4 2025 | 33.8 | — | 4.1 | — |
| Q1 2026 | 31.5 | — | 6.3 | — |
| Q2 2026 | 29.8 | -4.3% | 1 | -73.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Gorilla Technology Group Inc. (GRRR), Zumiez Inc. (ZUMZ), Lightbridge Corporation (LTBR), Z Squared Inc. (ZSQR), Foghorn Therapeutics Inc. (FHTX), EGH Acquisition Corp. (EGHA)